Skip to main content

Abdominal Aortic Aneurysm (AAA)

Cardiovascular
1
Pipeline Programs
5
Companies
5
Clinical Trials
1 recruiting
0
Approved Products

Pipeline by Development Stage

Preclinical
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
On Market
0
0
0
1
0
0
0
Early DiscoveryClinical DevelopmentMarket

Cardiovascular is a $69.4B mature market dominated by anticoagulants and metabolic therapies with stable blockbuster portfolios.

$69.4B marketMature→ Stable30 products15 companies

Key Trends

  • FXa inhibitors (ELIQUIS, XARELTO) command 62% of market spending, creating limited room for new entrants
  • SGLT2 inhibitors gaining traction in heart failure indication, signaling expansion beyond traditional anticoagulation
  • Multiple patent cliffs (JANUVIA 2027, OPSUMIT 2029) create near-term revenue vulnerability but reinvestment pressure

Career Verdict

Strong choice for commercial, clinical operations, and device integration roles; limited opportunity for innovative pipeline development given market maturity.

AI-generated market analysis based on FDA, CMS, ClinicalTrials.gov, and hiring data

Market Leaders

#1ELIQUISStable
$18.3B
#2JARDIANCEGrowing
$8.8B
#3XARELTOStable
$6.3B
#4FARXIGAGrowing
$4.3B
AstraZeneca·Peak15.4yr
#5JANUVIADeclining
$4.1B
Merck & Co.·LOE_Approaching1.0yr

Drug Class Breakdown

FXa Inhibitors (Apixaban/Rivaroxaban)
$42.8B(62%)

Mature, stable revenue base

SGLT2 Inhibitors
$13.1B(19%)

Growing in heart failure and renal indications

DPP4 Inhibitors
$4.1B(6%)

Declining as LOE approaches 2027

ARBs and Combination Therapies
$3.4B(5%)

Stable in heart failure management

Endothelin Receptor Antagonists and Prostacyclin Agonists
$1.8B(3%)

Niche pulmonary hypertension market

Career Outlook

Stable

Cardiovascular careers are stable but not expanding; the market is mature, dominated by blockbuster franchises with predictable commercial cycles and patent cliffs. Professionals entering this space should expect strong compensation (Commercial $210K avg, Medical Affairs $201K avg) but limited opportunity to drive breakthrough innovation. Device company roles offer better growth trajectories than pharma, particularly in remote monitoring, diagnostics, and patient engagement technologies.

Breaking In

Target device companies (Abbott, Medtronic) for growth potential; if joining pharma, focus on Commercial or Clinical Operations roles where hiring is active and compensation is competitive.

For Experienced Professionals

Leverage cardiovascular expertise to move into medical device strategy, digital health partnerships, or adjacent therapeutic areas; R&D opportunity is limited and may require lateral moves to access innovation-focused roles.

In-Demand Skills

Healthcare economics and payer management (anticoagulation safety monitoring, cost-effectiveness)Real-world evidence generation (postmarket surveillance for FXa inhibitors)Digital health and remote patient monitoring integrationClinical trial execution in large, established patient populationsRegulatory expertise in label expansions (SGLT2 inhibitor indications)

Best For

Commercial/Sales roles (mature market execution)Medical Science Liaisons (managing healthcare provider relationships on established therapies)Clinical Operations/Project Managers (managing large Phase 3/4 programs)Regulatory Affairs (label expansion strategy, patent cliff preparation)Health Economics and Outcomes Research (demonstrating value in competitive anticoagulation market)

Hiring Landscape

$130K-$210K

Cardiovascular hiring is concentrated in device companies (Abbott 337, Medtronic 317) rather than pharma, reflecting the therapeutic area's reliance on hardware solutions and patient management infrastructure. Pharma hiring (Johnson & Johnson 261, Bristol Myers Squibb 52) is heavily weighted toward Commercial (468 roles) and Clinical Operations (296 roles), with minimal R&D investment (14 roles). Medical device integration and remote patient monitoring expertise are increasingly valued as the market consolidates.

1,386
Open Roles
5
Companies Hiring
5
Departments

Top Hiring Companies

337Growing
317Growing

By Department

Commercial(34%)
$210K
Clinical Operations(21%)
$180K
Engineering(13%)
$145K
Medical Affairs(1%)
$201K
Research & Development(1%)
$194K

Device companies offer more growth opportunities; pharma roles are high-paying but oriented toward mature market execution rather than innovation.

Competitive Landscape

5 companies ranked by most advanced pipeline stage

Sandoz
SandozAustria - Kundl
1 program
1
ACZ885Phase 21 trial
Active Trials
NCT02007252Terminated65Est. Oct 2015
Endoron Medical
Endoron MedicalIsrael - Kfar Saba
1 program
Aortoseal Endostapling SystemN/A1 trial
Active Trials
NCT06586021Recruiting25Est. Nov 2029
Medtronic
MedtronicNJ - Phillipsburg
1 program
Duplex ultra sound screening for abdominal aortic aneurysmsN/A1 trial
Active Trials
NCT02306304Completed913Est. Jan 2017
Philips
PhilipsNetherlands - Amsterdam
1 program
Endovascular Aortic RepairN/A1 trial
Active Trials
NCT01480206Completed58Est. Aug 2021
Endologix
EndologixCA - Irvine
1 program
Nellix SystemN/A1 trial
Active Trials
NCT01726257Completed333Est. Dec 2022

Trial Timeline

Clinical trial activity over time

2021
2022
2023
2024
2025
2026
2027
2028
2029
SandozACZ885
Endoron MedicalAortoseal Endostapling System
MedtronicDuplex ultra sound screening for abdominal aortic aneurysms
EndologixNellix System
PhilipsEndovascular Aortic Repair

Clinical Trials (5)

Total enrollment: 1,394 patients across 5 trials

ACZ885 for the Treatment of Abdominal Aortic Aneurysm

Start: Dec 2013Est. completion: Oct 201565 patients
Phase 2Terminated
NCT06586021Endoron MedicalAortoseal Endostapling System

Evaluation of the Aortoseal™ for Sealing and Fixation of AAA Endovascular Grafts to Aortic Wall

Start: Feb 2024Est. completion: Nov 202925 patients
N/ARecruiting
NCT02306304MedtronicDuplex ultra sound screening for abdominal aortic aneurysms

Ultra-sound for AAA Screening in Smoking Israeli Arab Men

Start: Jan 2015Est. completion: Jan 2017913 patients
N/ACompleted

Safety and Effectiveness Study of Endovascular Abdominal Aortic Aneurysm Repair Using the Nellix® System

Start: Dec 2013Est. completion: Dec 2022333 patients
N/ACompleted
NCT01480206PhilipsEndovascular Aortic Repair

Overlay of 3D Scans on Live Fluoroscopy for Endovascular Procedures in the Hybrid OR

Start: Sep 2011Est. completion: Aug 202158 patients
N/ACompleted

Related Jobs in Cardiovascular

Phase Legend

PreclinicalLab & animal studies
Phase 1Safety & dosing
Phase 2Efficacy testing
Phase 3Large-scale trials
On MarketApproved & available

Key Insights

1 actively recruiting trials targeting 1,394 patients
5 companies competing in this space

The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.